ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
 - EconoTimes)
NEW ORLEANS, Oct. 17, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Dr. Reddy’s investors should visit us at https://www.claimsfiler.com/cases/view-dr-reddys-laboratories-ltd-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
